Review article: Medical therapy for fistulizing Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 9, 2006, Pages 1283-1293

  Bressler, B ^a,b   Sands, B E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DISULFIRAM; DRUG ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PLACEBO; PREDNISONE; TACROLIMUS; THALIDOMIDE; TIOGUANINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; COLON FISTULA; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPEPSIA; GINGIVA HYPERPLASIA; GOLD STANDARD; HEADACHE; HIRSUTISM; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; INFECTION; INSOMNIA; KIDNEY DISEASE; LEUKOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MEDLINE; NAUSEA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; SIDE EFFECT; TASTE DISORDER; TOXIC HEPATITIS; TREMOR;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CIPROFLOXACIN; CROHN DISEASE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL FISTULA; METRONIDAZOLE;

EID: 33750029307     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03126.x     Document Type: Review

References (66)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA 1932; 99: 1323-9.
2. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-80.
3. Schwartz DA, Wiersema MJ, Dudiak KM. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evolution of Crohn's perianal fistulas. Gastroenterology 2001; 121: 1064-72.
4. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med 1980; 302: 981-7.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulae in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
6. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, double-blind, placebo controlled trial. Gastroenterology 2003; 125: 380-8.
7. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol 2004; 2: 376-8.
8. Sparberg M, Kirnser JB. Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 1966; 11: 865-80.
9. Jones JH, Lennard-Jones JF. Corticosteroids and corticotropin in the treatment of Crohn's disease. Gut 1966; 7: 181-7.
10. Malchow H, Ewe EK, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
11. Bernstein LH, Frank MS, Brandt LJ, Boley SH. Healing of perineal Crohn'sdisease with metronidazole. Gastroenterology 1980; 79: 357-65.
12. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's dieses: a follow-up study. Gastroenterology 1982; 83: 383-7.
13. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79: 533-40.
14. Turunen U, Farkkila M, Seppala K. Long-term treatment of peri-anal or fistulous Crohn's disease with ciprofloxacin. Scand J Gastroenterol 1989; 24 (Suppl. 48): 144.
15. Wolf J. Ciprofloxacin may be useful in Crohn's disease. Gastroenterology 1990; 98: A212 (abstract).
16. Casparian JM, Luchi M, Moffat RE, Hinthorn D. Quinolones and tendon ruptures. South Med J 2000; 93: 488-91.
17. Solomon M, McLeod R, O'Connor B, Steinhart A, Greenberg G, Cohen Z. Combination ciprofloxacin and metronidazole in severe perineal Crohn's disease. Can J Gastroenterol 1993; 7: 571-3.
18. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1113-20.
19. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 1329-36.
20. West RL, van der Woude CJ, Endtz HP, et al. Perianal fistulas in Crohn's disease are predominately colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci 2005; 50: 1260-3.
21. Solem CA, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Sandborn WJ. Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol 2002; 97: 2300-5.
22. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
23. Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30: 294-8.
24. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985; 30: 58-64.
25. O'Brien J, Bayless T, Bayless J. Use of azathioprine in the treatment of Crohn's disease. Gastroenterology 1991; 101: 39-46.
26. Greenstein A, Present D, Sachar D, et al. Gastric fistulas in Crohn's disease. Report of cases. Dis Colon Rectum 1989; 32: 888-92.
27. Margolin M, Korelitz B. Management of bladder fistula in Crohn's disease. J Clin Gastroenterol 1989; 11: 399-402.
28. Glass RE, Ritchie JK, Lennard-Jones JE, Hawley PR, Todd IP. Internal fistulas in Crohn's disease. Dis Colon Rectum 1985; 28: 557-61.
29. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.
30. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
31. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.
32. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; 18: CD000297.
33. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993; 88: 627-30.
34. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39: 374-80.
35. Egan L, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93: 442-8.
36. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common targer of cyclophilin-cylcosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
37. Flanagan WM, Corthesy B, Bram RJ, Crabtreee GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 1991; 352: 803-7.
38. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997; 92: 876-9.
39. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulzae. Inflamm Bowel Dis 1999; 5: 239-45.
40. Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30: 200-2.
41. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
42. Sands BE, Blank MA, Patel K, van Deventer SJH. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004; 2: 912-20.
43. Lichtenstein GR, Yan S, Bala M, Blank M, Sands B. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
44. Miheller P, Muzes G, Zagoni T, Toth M, Raez K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis 2006; 24: 201-6.
45. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45: 771-5.
46. Sands BE, Blank MA, Diamond RH, Barrett JP, van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006; 23: 1127-36.
47. Wise PE, Schwartz DA. Management of perianal Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 426-30.
48. Singh B, McC Mortensen NJ, Jewell DP, George B. Perianal Crohn's disease. Br J Surg 2004; 91: 801-14.
49. Lichenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies fro Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
50. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006; 295: 2275-85.
51. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
52. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-53.
53. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601.
54. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542.
55. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
56. Vermeire S, Noman M, Van Assche G, Baert F. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32.
57. Arseneau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001; 120: 1640-56.
58. Ochsenkuhn T, Goke B, Sackman M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97: 2022-5.
59. Schwartz DA, White CM, Wise PE, Herline AJ. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fisulas. Inflamm Bowel Dis 2005; 11: 727-32.
60. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol 2004; 99: 82-8.
61. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352: 2193-201.
62. Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004; 16: 921-6.
63. Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004; 19: 427-34.
64. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278-87.
65. Lavy A, Yasin K. Octreaotide for enterocutaneous fistulas of Crohn's disease. Can J Gastroenterol 2003; 17: 555-8.
66. Noyer CM, Brandt LJ. Hyperbaric oxygen therapy for perineal Crohn's disease. Am J Gastroenterol 1999; 94: 318-21.